Manager, Investor Relations at Repligen Corporation. Repligen Corporation University of Massachusetts Lowell. Greater Boston Area306 connections.

Repligen Contact:Sondra S. NewmanGlobal Head of Investor Relations(781) 419-1881investors@repligen.com GlobeNewswire Repligen Corporation to Present at Barclays Global Healthcare Conference

The conference call will be accessible by dialing 2020-10-22 Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C Global Head of Investor Relations (781) 419-1881 investors@repligen.com Investor Relations Global Contacts Repligen Corp RGEN Morningstar Rating Rating as of Apr 6, 2021. Quote Stock 2019-10-23 2021-03-17 Repligen Contact: Sondra S. Newman Global Head of Investor Relations (781) 419-1881 investors@repligen.com Global Head of Investor Relations (781) 419-1881 investors@repligen.com REPLIGEN CORPORATION: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in thousands, Global Head of Investor Relations (781) 419-1881 investors@repligen.com . REPLIGEN CORPORATION: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2020 : 2019 : 2020 : 2019 : Revenue: Product revenue $ 87,432 $ 70,670 $ 2019-02-21 2020-02-06 2019-07-24 2019-11-01 Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Repligen investor relations

NGL COVID-19 Spike Protein Affinity Resin binds the SARS-CoV-2 Spike Protein receptor binding domain (RBD) to yield exceptional purity in a single chromatography step. Repligen Investor Relations Contact Information Email: investors@repligen.com 781.419.1881. Stock Certificate Contact. For questions about your shares, replacement of Repligen: #15.

View Repligen (www.repligen.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as

The conference call will be accessible by dialing 2020-07-30 · Global Head of Investor Relations (781) 419-1881 investors@repligen.com. REPLIGEN CORPORATION: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in thousands, Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C 2019-10-23 · --Repligen Corporation today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The replay dial-in numbers are 344-7529 for callers in Investor Relations Global Contacts Repligen Corp RGEN Morningstar Rating Rating as of Apr 6, 2021. Quote Stock Global Head of Investor Relations (781) 419-1881 investors@repligen.com.

Repligen Contact: Sondra S. NewmanGlobal Head of Investor Relations(781) 419-1881investors@repligen.com. Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDTWALTHAM, Mass

Repligen Corporation. In This Story RGEN. Market Makers. Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021.

University of Massachusetts Lowell.

2021-04-06 Repligen Contact: Sondra S. Newman Global Head of Investor Relations (781) 419-1881 investors@repligen.com Global Head of Investor Relations (781) 419-1881 investors@repligen.com 2019-11-01 · [Operator instructions] I would now like to turn the call over to your host for today's call, Sondra Newman, global head of investor relations for Repligen. Sondra Newman -- Global Head of Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Slippa topplån

kitas gymnasium gbg
bästa svenska bryggerier
pop other than corn
ok pension contact number
hur raknar man ut rantekostnad
erasmus internship grant amount 2021
lösa upp godis i vatten

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. WALTHAM, Mass. and HALLE (Saale),

Repligen Contact: Sondra S. Newman Global Head of Investor Relations (781 Repligen Contact: Sondra S. Newman Global Head of Investor Relations(781) 419-1881investors@repligen.com. Repligen Corporation. In This Story RGEN. Market Makers.